68Ga-Radiopharmaceutical
Gallium-68 is a versatile radionuclide widely used in PET imaging for its short half-life and high-resolution capabilities, enabling applications in oncology, cardiology, and inflammatory disease research. Alfa Cytology provides comprehensive preclinical services, from 68Ga radiopharmaceutical development to in vivo imaging studies, supporting the advancement of innovative diagnostics and therapeutics.
Overview of 68Ga-Based Radiopharmaceuticals
Gallium-68 is a positron-emitting radionuclide widely valued in PET imaging due to its short half-life of approximately 68 minutes, which balances imaging time with patient safety by minimizing radiation exposure. This short half-life enables efficient imaging workflows, allowing for rapid data acquisition and minimizing delay between synthesis and imaging. Additionally, 68Ga provides high-resolution images due to its optimal positron emission energy, enhancing the clarity and sensitivity needed for precise disease localization. In recent years, the development of 68Ga-labeled drugs and imaging agents has expanded significantly, targeting a range of conditions in oncology, cardiology, and inflammatory diseases, among others.
Fig.1 The four main steps of the 68Ga-radiolabeling procedure. (Nelson BJB, et al., 2022)
68Ga Radiopharmaceuticals and Imaging Agents
More and more 68Ga-labeled compounds have been entering clinical trials, while clinical applications have already extended from oncology to cardiovascular diseases and inflammatory conditions. 68Ga also has an important role in the new discipline of theragnostic, which utilizes diagnostic and therapeutic functions and furthers precision medicine. Its capability for targeting specific molecular pathways has placed it as a key tool in future drug development.
- 68Ga-DOTATATE: Gallium-68 labeled imaging agent targets somatostatin receptors (SSTR) and is widely used in PET for diagnosing neuroendocrine tumors (NETs) with high sensitivity and specificity.
- 68Ga-PSMA: Applied in imaging for prostate cancer, 68Ga-PSMA has become a crucial tool in detecting metastatic and recurrent prostate cancer. Ongoing clinical trials worldwide are expected to lead to broader regulatory approval shortly.
Our Services
Our services make provision in all aspects of development by various clients of 68Ga-labeled radiopharmaceuticals, imaging agents, and tracers. We provide specific solutions starting from early design to preclinical evaluation, including but not limited to the following.
Imaging and Tracer Agent Development Services
We design 68Ga-labeled imaging agents and tracers to advance the development of diagnostics related to cancer, cardiovascular, neurodegenerative and inflammatory diseases. Our service encompasses ligand and tracer design, optimization up to radiolabeling.
Target Discovery for 68Ga-Radiopharmaceutical
Our extensive experience enables us to focus on a range of specific targets, such as PSMA, somatostatin receptors, HER2, dopamine receptors, amyloid beta plaques, TSPO, infection markers, angiotensin II receptors, and cardiac function markers.
Design and Optimization of 68Ga-Labeled Compounds
We design and synthesize efficient 68Ga-labeled compounds and ligands, focusing on the optimization of chelators toward enhanced stability and bioavailability.
68Ga Conjugation Service
68Ga exhibits excellent coordination properties, allowing it to effectively bind with a variety of molecules to form stable complexes.
Utilizing high-resolution PET imaging, we deliver actionable data on in vivo targeting of 68Ga-labeled compounds, aiding drug discovery and disease research applications.
- Oncological Imaging: We use 68Ga-labeled compounds in preclinical studies to precisely locate neuroendocrine tumors, prostate cancer, and so on, aiding early-stage research on tumor behavior and.
- Cardiovascular Imaging: 68Ga tracers support preclinical models of coronary artery disease and atherosclerosis, helping to develop early diagnostic and therapeutic strategies.
- Imaging of Inflammatory and Infectious Conditions: Our 68Ga-labeled agents are used in preclinical imaging to monitor chronic inflammation and infections, providing insights into disease progression and drug efficacy.
Alfa Cytology specialize in the development of state-of-the-art 68Ga radiopharmaceuticals, integrating efforts from radiochemistry laboratories to advanced imaging techniques. Leveraging our expertise in radiochemistry and nuclear medicine, we ensure seamless transitions from early research to preclinical development stages. For more information about our 68Ga radiopharmaceutical development services or to discuss your project, please contact us.
Reference
- Nelson BJB, et al. (2022). Good practices for 68Ga radiopharmaceutical production. EJNMMI Radiopharm Chem. 22;7(1):27.
For research use only. Not intended for any clinical use.
Related Service
